[1] LAVERNIA CJ, SIERRA RJ, GRIECO FR. Osteonecrosis of the femoral head. J Am Acad Orthop Surg. 1999;7(4):250-261.
[2] CHUGHTAI M, PIUZZI NS, KHLOPAS A, et al. An evidence-based guide to the treatment of osteonecrosis of the femoral head.Bone Joint J. 2017;99-B(10):1267-1279.
[3] XU J, GONG H, LU S, et al. Animal models of steroid-induced osteonecrosis of the femoralhead—a comprehensive research review up to 2018.Int Orthop. 2018;42(7):1729-1737.
[4] IKEUCHI K, HASEGAWA Y, SEKI T, et al. Epidemiology of nontraumatic osteonecrosis of the femoral head in Japan.Mod Rheumatol. 2015;25(2):278-281.
[5] WANG A, REN M, WANG J. The pathogenesis of steroid-induced osteonecrosis of the femoral head: A systematic review of the literature.Gene. 2018 ;671:103-109.
[6] 邢冰琪,孙洪胜,傅春升,等.补肾活血法治疗激素性股骨头坏死的研究进展[J].中国药业,2013,22(24):15-17.
[7] POWELL C, CHANG C, GERSHWIN ME. Current concepts on the pathogenesis and natural history of steroid-induced osteonecrosis.Clin Rev Allergy Immunol. 2011;41(1):102-113.
[8] 夏炳江,童培建,肖鲁伟,等.大鼠激素性股骨头坏死肾阳虚型病证结合模型构建与评价的实验研究[J].中华中医药学刊,2013, 31(2):301-304+454.
[9] 赵万军,肖鲁伟,周辉,等.激素性股骨头坏死中医病机学实验研究[J].中国中医骨伤科杂志,2005,13(2):23-27.
[10] 吴云刚,肖鲁伟,童培建.右归饮对激素性股骨头坏死患者股骨近端骨髓骨活性影响的实验研究[J].中国骨伤,2009,22(2):115-117.
[11] 肖鲁伟,童培建,赵万军,等.激素诱导的股骨头坏死与肾阳虚证之间的关系[J].中医正骨,1998,10(4):4-5+64.
[12] 宋才渊,沈兴潮,吕帅杰,等.右归饮对激素性股骨头坏死大鼠血液骨矿物质盐及骨密度的影响[J].中医杂志,2015,56(14):1239-1242.
[13] 马清林,杜丽东,臧凯宏,等.网络药理学在复方中药研究中的应用及其存在的问题[J].中国当代医药,2019,26(26):21-24.
[14] 赵炳聪,李亚鸿,解红霞.网络药理学在中药复方作用机制研究中的应用[J].中国中医药信息杂志,2020,27(3):133-136.
[15] 朱振康,李陶冶,杜文喜,等.右归饮对类固醇激素性股骨头坏死大鼠成骨-破骨体外共育体系中破骨细胞分化的影响[J].中华骨质疏松和骨矿盐疾病杂志,2013,6(4):327-333.
[16] 童培建,胡柏松,金红婷,等.右归饮对激素性股骨头坏死大鼠体外诱导培养成骨细胞作用的研究[J].中国骨伤,2010,23(1):23-27.
[17] 宋才渊,沈兴潮,吕帅杰,等.右归饮治疗激素性股骨头坏死的研究[J].中华中医药杂志,2015,30(4):1204-1207.
[18] 倪云锋,金星,何帮剑.右归饮联合金葡液治疗早期激素性股骨头坏死72例[J].山东中医杂志,2011,30(8):548-549.
[19] 苗金波,焦宗乾,楚晓笋.中西医结合治疗股骨头坏死60例[J].山西中医,2010,26(11):23.
[20] 魏秋实,杨帆,陈哓俊,等.激素性与酒精性股骨头坏死患者骨标本坏死区域病理与显微结构特点分析[J].中国修复重建外科杂志,2018,32(7):866-872.
[21] CHEN GH, ZHANG XL, CHEN H, et al. miR-22 represses osteoblast viability with ESR1 presenting a direct target and indirectly inactivating p38 MAPK/JNK signaling.J Gene Med. 2020 ;14:e3174.
[22] SHANG DP, LIAN HY, FU DP, et al. Relationship between estrogen receptor 1 gene polymorphisms and postmenopausal osteoporosis of the spine in Chinese women.Genet Mol Res. 2016;15(2). doi: 10.4238/gmr.15028106.
[23] MELVILLE KM, KELLY NH, KHAN SA, et al. Female mice lacking estrogen receptor-alpha in osteoblasts have compromised bone mass and strength.J Bone Miner Res. 2014;29(2): 370-379.
[24] SOMANATH PR, RAZORENOVA OV, CHEN J, et al. Akt1 in endothelial cell and angiogenesis.Cell Cycle. 2006;5(5):512-518.
[25] VANDOORNE K, MAGLAND J, PLAKS V, et al. Bone vascularization and trabecular bone formation are mediated by PKB alpha/Akt1 in a gene-dosage-dependent manner: in vivo and ex vivo MRI.Magn Reson Med. 2010;64(1):54-64.
[26] MUKHERJEE A, LARSON EA, KLEIN RF, et al. Distinct actions of akt1 on skeletal architecture and function.PLoS One. 2014;9(3):e93040.
[27] MUKHERJEE A, ROTWEIN P. Selective signaling by Akt1 controls osteoblast differentiation and osteoblast-mediated osteoclast development.Mol Cell Biol. 2012;32(2):490-500.
[28] CHOI YH, CHOI HJ, LEE KY, et al. Akt1 regulates phosphorylation and osteogenic activity of Dlx3.Biochem Biophys Res Commun. 2012; 425(4):800-805.
[29] ULICI V, HOENSELAAR KD, AGOSTON H, et al. The role of Akt1 in terminal stages of endochondral bone formation: angiogenesis and ossification.Bone. 2009;45(6):1133-1145.
[30] 童培建,厉驹,季卫锋,等.干细胞凝胶复合体加右归饮修复家兔软骨缺损的实验研究[J].中医正骨,2005,17(6):3-5+65.
[31] 何伟.如何把握股骨头坏死患者的保髋治疗时机[J].中国骨与关节杂志,2016,5(2):82-86.
[32] WATTERS RJ, HARTMAIER RJ, OSMANBEYOGLU HU, et al. Oesterreich. Steroid receptor coactivator-1 can regulate osteoblastogenesis independently of estrogen. Mol Cell Endocrinol. 2017;448:21-27.
[33] WANG Y, LIU Y, ZHANG M, et al. Inhibition of PTGS1 promotes osteogenic differentiation of adipose-derived stem cells by suppressing NF-kB signaling.Stem Cell Res Ther. 2019;10(1):57.
[34] 程晓刚,粟永萍,罗成基,等.C-Jun蛋白对糖皮质激素受体表达及转录激活能力的影响[J].免疫学杂志,2005(S1):112-115.
[35] 乔丽,余月明,曹礼应,等.45例肾病综合征患者肾组织c-Jun和c-Fos的表达及意义[J].重庆医学,2010,39(1):16-18.
[36] 林华,魏海燕,蒋青,等.原发性骨质疏松骨组织c-fos、c-jun和p53基因的表达[J].中国骨肿瘤骨病,2003,3(6):368-371.
[37] 张国君,张欢,陈念慈,等.NCOA2促进急性B淋巴细胞白血病细胞增殖及下游信号通路的生物信息学分析[J].解剖科学进展, 2019,25(4):368-372.
[38] 李艳,孙文星,徐春瑛,等.NCOA2核心启动子甲基化分析及其与肾周和皮下脂肪组织差异表达的关系[J].南京农业大学学报, 2014,37(4):131-136.
[39] 顾艺婧,傅稼耀,武文婧,等.槲皮素通过抗骨相关细胞衰老作用治疗雌激素缺乏骨质疏松症的初步研究[J].同济大学学报(医学版), 2019,40(3):274-280.
[40] 郑红,唐薇,角建林,等.槲皮素通过促进成骨分化治疗去势骨质疏松症大鼠的分子机制[J].中药药理与临床,2017,33(5):16-20.
[41] 吴素珍,刘霞,李加林,等.槲皮素对兔软骨细胞增殖的影响[J].时珍国医国药,2014, 25(1):16-17.
[42] WINZER M, RAUNER M, PIETSCHMANN P. Glycitein decreases the generation of murine osteoclasts and increases apoptosis.Wien Med Wochenschr. 2010;160(17-18):446-451.
[43] YOSHIDA H, TERAMOTO T, IKEDA K,et al. Glycitein effect on suppressing the proliferation and stimulating the differentiation of osteoblastic MC3T3-E1 cells.Biosci Biotechnol Biochem. 2001;65(5):1211-1213.
[44] TAO X, QI Y, XU L, et al. Dioscin reduces ovariectomy-induced bone loss by enhancing osteoblastogenesis and inhibiting osteoclastogenesisPharmacol Res. 2016;108: 90-101.
[45] BOSE M , CHAKRABORTY M, BHATTACHARYA S, et al.Prevention of arthritis markers in experimental animal and inflammation signalling in macrophage by Karanjin isolated from Pongamia pinnata seed extract. Phytother Res 2014;28(8):1188-1195. |